Medifast Sees FY23 EPS $8.65-$9.55 Vs $8.52 Est.; Revenue $1.05B-$1.07B Vs $1.09B Est.; Guidance Assumes A 20.5%-21.5% Effective Tax Rate
Portfolio Pulse from Benzinga Newsdesk
Medifast has provided its FY23 guidance, expecting EPS to be between $8.65 and $9.55, compared to the estimated $8.52. The company also anticipates revenue to be in the range of $1.05B to $1.07B, lower than the estimated $1.09B. The guidance assumes a 20.5% to 21.5% effective tax rate.
November 06, 2023 | 9:35 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Medifast's FY23 EPS guidance is higher than estimates, but revenue guidance is lower. This mixed outlook could lead to uncertainty among investors.
Medifast's higher than expected EPS guidance for FY23 indicates potential profitability, which could positively impact the stock. However, the lower than expected revenue guidance could negatively impact the stock as it suggests potential sales growth issues. The mixed outlook could lead to uncertainty among investors, resulting in a neutral short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100